Zenflow

Zenflow is a clinical-stage medical device company pioneering a new treatment for benign prostatic hyperplasia (BPH). The company's procedure is designed to be gentle, effective, and fast-recovering, addressing patient frustrations with the side effects of drugs and the discomfort of current minimally invasive therapies. With a leadership team boasting deep experience in medical device development, regulatory affairs, and commercialization, Zenflow is advancing its technology through clinical evaluation. The company targets a massive and growing market of men over 50, aiming to capture significant share by offering a superior patient experience.

Catheter-based medical device for gentle, minimally invasive treatment of BPH, designed to provide lasting symptom relief without cutting, burning, or piercing tissue, enabling recovery within hours.

Zenflow competes in the Minimally Invasive Surgical Therapy (MIST) segment for BPH, against established technologies like laser ablation (e.g., GreenLight), water vapor therapy (Rezūm), and temporary implantable devices (UroLift, iTind). Its differentiation is predicated on a gentler mechanism and faster recovery, aiming to set a new standard for patient tolerability within this competitive category.